Influenza vaccine
The present invention provides an immunogenic influenza composition in a dose volume suitable for human use, comprising an influenza virus antigen or antigenic preparation thereof and an adjuvant composition comprising an oil-in-water emulsion, wherein said oil-in-water emulsion comprises a metabolisable oil at a level of below 11 mg and an emulsifying agent at a level of below 5 mg and optionally a tocol or a sterol at a level of below 12 mg. Suitably the amount of influenza antigen per strain per dose is 15 μg HA or a low amount such as less than 15 μg HA.
1. An immunogenic influenza composition in a dose volume suitable for human use comprising an influenza virus antigen or antigenic preparation in combination with an oil-in-water emulsion adjuvant, wherein the adjuvant comprises 0.31% to 1.25% (v/v) squalene, 0.11% to 0.45% (v/v) emulsifying agent, and 0.31% to 1.25% (v/v) tocol; wherein the adjuvant does not comprise 3D-MPL and does not comprise a saponin; and wherein the influenza virus antigen or antigenic preparation comprises 0.5 to 7 μg of haemagglutinin (HA) per dose per influenza strain.
2. The immunogenic composition of claim 1 , wherein the adjuvant is selected from the group consisting of: (i) an adjuvant comprising 1.25% (v/v) squalene, 0.45% (v/v) emulsifying agent, and 1.25% (v/v) tocol; (ii) an adjuvant comprising 0.63% (v/v) squalene, 0.23% (v/v) emulsifying agent, and 0.63% (v/v) tocol; and (iii) an adjuvant comprising 0.31% (v/v) squalene, 0.11% (v/v) emulsifying agent, and 0.31% (v/v) tocol.
3. The immunogenic composition of claim 1 , wherein said emulsifying agent is a non-ionic surfactant.
4. The immunogenic composition of claim 3 , wherein said emulsifying agent is a polyoxyethylene sorbitan monooleate, a sorbitan trioleate, or a mixture of both.
5. The immunogenic composition of claim 1 , wherein said tocol is alpha-tocopherol.
6. The immunogenic composition of claim 1 , wherein the adjuvant further comprises a TLR ligand of a TLR receptor selected from: TLR-1, TLR-2, TLR-3, TLR-4, TLR-7, TLR-8, and TLR-9 or combination thereof.
7. The immunogenic composition of claim 6 , wherein said TLR ligand is TLR-4 ligand.
8. The immunogenic composition of claim 1 , wherein said virus antigen or antigenic preparation comprises 1 to 5 μg HA per human dose per influenza strain.
9. The immunogenic composition of claim 1 , wherein said virus antigen or antigenic preparation comprises 3.8 μg HA per human dose per influenza strain.
10. The immunogenic composition of claim 1 , wherein said virus antigen or antigenic preparation comprises 1.9 μg HA per human dose per influenza strain.
11. The immunogenic composition of claim 1 , wherein said composition is a monovalent composition comprising a virus antigen or antigenic preparation from one influenza virus strain.
12. The immunogenic composition of claim 11 , wherein the influenza virus strain is selected from the group consisting of: H5N1, H9N2, H5N8, H5N9, H7N4, H7N7, H2N2, H10N7, H5N2, H7N2, H7N1, and H7N3.
13. The immunogenic composition of claim 11 , wherein the influenza virus strain is selected from the group consisting of: H2, H5, H9, H7, or H6.
14. The immunogenic composition of claim 13 , wherein the virus antigen or antigenic preparation comprises 1 to 5 μg HA per human dose per influenza strain.
15. The immunogenic composition of claim 13 , wherein the virus antigen or antigenic preparation comprises 3.8 μg HA per human dose per influenza strain.
16. The immunogenic composition of claim 13 , wherein the virus antigen or antigenic preparation comprises 1.9 μg HA per human dose per influenza strain.
17. The immunogenic composition of claim 1 , wherein said composition is a multivalent composition comprising a virus antigen or antigenic preparation from at least two influenza strains.
18. The immunogenic composition of claim 17 , wherein said composition comprises a virus antigen or antigenic preparation from at least three influenza seasonal (interpandemic) strains.
19. The immunogenic composition of claim 17 , wherein said multivalent composition comprises a virus antigen or antigenic preparation selected from the group consisting of:
two interpandemic A strains chosen from the group of: H1N1 and H3N2 and two B strains chosen from the group of: B/yamagata and B/Victoria;
two interpandemic A strains chosen from the group of: H1N1 and H3N2 and one B strain chosen from the group of: B/yamagata and B/Victoria; and
two interpandemic A strains chosen from the group of: H1N1 and H3N2, one pandemic A strain, wherein the strain is H5N1; and one B strain chosen from the group of B/yamagata and B/Victoria.
20. A vaccine comprising the immunogenic composition of claim 1 and a pharmaceutically acceptable excipient.
21. The immunogenic composition of claim 1 , wherein the influenza virus antigen or antigenic preparation thereof is from influenza virus grown in eggs or in cell culture.
22. The immunogenic composition of claim 1 , wherein the influenza virus antigen or antigenic preparation thereof comprises a whole virus, a split virus, a virosome or one or more purified antigen selected from the group consisting of: HA, NA, M1, and M2.
23. The immunogenic composition of claim 22 , wherein the influenza virus antigen or antigenic preparation thereof comprises one or more purified antigen and said purified antigen is prepared from influenza virus grown in mammalian, avian or insect cells.
24. The immunogenic composition of claim 1 , wherein the adjuvant comprises 1.25% (v/v) squalene, 0.45% (v/v) emulsifying agent, and 1.25% (v/v) tocol.
25. The immunogenic composition of claim 1 , wherein the adjuvant comprises 0.63% (v/v) squalene, 0.23% (v/v) emulsifying agent, and 0.63% (v/v) tocol.
26. The immunogenic composition of claim 1 , wherein the adjuvant comprises 0.31% (v/v) squalene, 0.11% (v/v) emulsifying agent, and 0.31% (v/v) tocol.
27. The immunogenic composition of claim 1 , wherein the dose volume is between 0.25 ml and 0.5 ml.
28. The immunogenic composition of claim 1 , wherein the dose volume is between 0.5 ml and 1 ml.
29. The immunogenic composition of claim 1 , wherein the dose volume is between 1 ml and 1.5 ml.
30. The immunogenic composition of claim 1 , wherein the influenza virus antigen or antigenic preparation thereof comprises a split virus.
31. The immunogenic composition of claim 1 , wherein the dose volume is between 0.20 ml and 1.5 ml.
32. The immunogenic composition of claim 1 , wherein the dose volume is 0.25 ml.
33. The immunogenic composition of claim 1 , wherein the emulsifying agent is polysorbate 80.
34. The immunogenic composition of claim 1 , wherein the composition is a multivalent composition comprising a virus antigen or antigenic preparation from three influenza strains.
35. The immunogenic composition of claim 1 , wherein the composition is a multivalent composition comprising a virus antigen or antigenic preparation from four influenza strains.
36. A method for making a vaccine, the method comprising mixing an immunogenic composition with a pharmaceutically acceptable excipient, wherein the immunogenic composition is in a dose volume suitable for human use, wherein the immunogenic composition comprises an influenza virus antigen or antigenic preparation in combination with an oil-in-water emulsion adjuvant, wherein the influenza virus antigen or antigenic preparation comprises 0.5 to 7 μg of haemagglutinin (HA) per dose per influenza strain, wherein the adjuvant is selected from the group consisting of: (i) an adjuvant comprising 1.25% (v/v) squalene, 0.45% (v/v) emulsifying agent, and 1.25% (v/v) tocol; (ii) an adjuvant comprising 0.63% (v/v) squalene, 0.23% (v/v) emulsifying agent, and 0.63% (v/v) tocol; and (iii) an adjuvant comprising 0.31% (v/v) squalene, 0.11% (v/v) emulsifying agent, and 0.31% (v/v) tocol.
37. A method of immunising a human host against disease caused by influenza infection, the method comprising administering to the host the vaccine of claim 20 , wherein the vaccine comprises comprises 1 to 5 μg HA per human dose per influenza strain.
38. The method of claim 37 , wherein the human host is an adult aged 18-50, an adult aged 18-65 or a child aged 0-18.
39. The method as claimed in claim 37 , wherein the vaccine induces a cross-reactive CD4 T helper response against the antigen or antigenic preparation thereof, which cross-reactive CD4 T helper response is improved compared to that obtained with a non-adjuvanted composition.
40. The method as claimed in claim 37 , wherein the vaccine induces a cross-reactive humoral immune response against the antigen or antigenic preparation thereof, which cross-protective humoral response is improved compared to that obtained with a non-adjuvanted composition.